A potential precision medicine approach for treating vision loss
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
The study was published in Scientific Reports, and marks the first time researchers have replaced a defective gene associated with a sensory disease in stem cells that were derived from a patient’s tissue.
“Our vision is to develop a personalized approach to treating eye disease,” says Stephen Tsang, MD, PhD, the László Z. Bitó Associate Professor of Ophthalmology and associate professor of Pathology & Cell Biology at CUMC, ophthalmologist at NewYork-Presbyterian/Columbia, and one of the study’s senior authors. “We still have some way to go, but we believe that the first therapeutic use of CRISPR will be to treat an eye disease. Here we have demonstrated that the initial steps are feasible.”
In the study, the researchers created stem cells from a sample of skin that was taken from a patient with retinitis pigmentosa. As the patient-derived stem cells still harbored the disease-causing mutation, the teams used CRISPR to repair the defective gene. The stem cells can potentially be transformed into healthy retinal cells and transplanted back into the same patient to treat vision loss.
“The X-linked form of retinitis pigmentosa is an ideal candidate for a precision medicine approach because a common mutation accounts for 90% cases,” Tsang explains. Using CRISPR —which is easily adaptable to diverse sequences of DNA, and allows for fast and accurate editing —scientists can take a patient’s own cells and make pinpoint repairs specific to that individual’s genome.
Because the corrections are made in cells derived from the patient’s own tissue, doctors can re-transplant the cells with fewer fears of rejection by the immune system. Previous clinical trials have shown that generating retinal cells from embryonic stem cells and using them for transplantation is a safe and potentially effective procedure.
In this paper, the researchers targeted one of the most common variants of retinitis pigmentosa, which is caused by a single mistake in a gene called RGPR. The composition of RGPR—which contains many repeats and tight-binding nucleotide pairs—make it a difficult gene to edit. The researchers say that preliminary success with RGPR is therefore promising for treating other forms of the condition caused by mutations in other genes.
The current treatment for retinitis pigmentosa recommended by the National Institutes of Health—consuming high doses of vitamin A—slows down vision loss but does not cure the disease.
Other types of gene therapies for are currently undergoing clinical trials. Unlike CRISPR-based methods, these therapies introduce stretches of DNA that supplement some of the activity of the defective gene, but do not directly correct the original mutation. Follow-up studies have shown that any gains in vision from these gene supplementation therapies wane over time.
A CRISPR-driven precision medicine approach to treating retinitis pigmentosa may improve upon current therapies and restore a patient’s vision because CRISPR, with its pinpoint accuracy, can correct the fundamental genetic defect responsible for the disease. However, CRISPR technology has not yet been approved for use in humans.
The Latest on: Retinitis pigmentosa
via Google News
The Latest on: Retinitis pigmentosa
Greensburg man saw life despite blindness
on May 24, 2019 at 1:23 pm
He would be right in there helping with whatever.” Mr. Dallo became blind at age 12 from retinitis pigmentosa, a genetic condition passed down from mother to son, said his nephew, Bob Dallo. ... […]
ProQR Therapeutics: Near-Term Readout On The Horizon
on May 22, 2019 at 6:24 pm
Interim data from the phase 1/2 STELLAR trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa provides a near-term catalyst. The stock is a Speculative Buy. ... […]
Edison Investment Research Limited: Edison Issues Update on ReNeuron Group (RENE)
on May 20, 2019 at 5:20 am
LONDON, UK / ACCESSWIRE / May 20, 2019 / ReNeuron's year-end update summarised its recent clinical progress in the human retinal progenitor cell (hRPC) programme in retinitis pigmentosa (RP), which ... […]
OliX Pharmaceuticals Expands Ocular Disease Pipeline; Adds OLX304A for the Treatment of Retinitis Pigmentosa
on May 9, 2019 at 6:31 pm
SUWON, South Korea, May 9, 2019 /PRNewswire/ -- OliX Pharmaceuticals, Inc. (226950.KQ), a leading developer of RNAi therapeutics, announced today an expansion of its ocular disease pipeline. ... […]
Accuracy of a deep convolutional neural network in detection of retinitis pigmentosa on ultrawide-field images
on May 7, 2019 at 1:01 am
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for ... […]
Phase 2a study shows improved vision with stem cell therapy for retinitis pigmentosa
on May 1, 2019 at 1:42 pm
VANCOUVER, British Columbia — Human retinal progenitor cell therapy from ReNeuron Group is showing positive preliminary results in the company’s ongoing phase 1/2a clinical trial involving patients ... […]
Retinitis Pigmentosa Treatment Market Insights and Investment Opportunities
on April 26, 2019 at 7:51 am
New York, NY -- (SBWIRE) -- 04/26/2019 -- The market intelligence assessment on the Retinitis Pigmentosa Treatment market blends in the best of both qualitative and quantitative research techniques to ... […]
ReNeuron upbeat on early data from retinitis pigmentosa trials
on April 26, 2019 at 5:09 am
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views. (Sharecast News) - Cell-based therapeutics developer ... […]
Retinitis Pigmentosa (RP) Market - Report on Recent Adoption 2025
on April 25, 2019 at 6:25 am
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and ... […]
via Bing News